EP4313315A4 - CANCER THERAPY USING TOLL-LIKE RECEPTOR AGONISTS - Google Patents

CANCER THERAPY USING TOLL-LIKE RECEPTOR AGONISTS

Info

Publication number
EP4313315A4
EP4313315A4 EP22782201.2A EP22782201A EP4313315A4 EP 4313315 A4 EP4313315 A4 EP 4313315A4 EP 22782201 A EP22782201 A EP 22782201A EP 4313315 A4 EP4313315 A4 EP 4313315A4
Authority
EP
European Patent Office
Prior art keywords
toll
cancer therapy
receptor agonists
agonists
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22782201.2A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4313315A1 (en
Inventor
Steven C. KATZ
Bryan F. COX
David Benjamin Jaroch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trisalus Life Sciences Inc
Original Assignee
Trisalus Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trisalus Life Sciences Inc filed Critical Trisalus Life Sciences Inc
Publication of EP4313315A1 publication Critical patent/EP4313315A1/en
Publication of EP4313315A4 publication Critical patent/EP4313315A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
EP22782201.2A 2021-04-01 2022-03-31 CANCER THERAPY USING TOLL-LIKE RECEPTOR AGONISTS Pending EP4313315A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163169674P 2021-04-01 2021-04-01
US202263298589P 2022-01-11 2022-01-11
PCT/US2022/022801 WO2022212690A1 (en) 2021-04-01 2022-03-31 Cancer therapy using toll-like receptor agonists

Publications (2)

Publication Number Publication Date
EP4313315A1 EP4313315A1 (en) 2024-02-07
EP4313315A4 true EP4313315A4 (en) 2025-02-19

Family

ID=83456830

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22782201.2A Pending EP4313315A4 (en) 2021-04-01 2022-03-31 CANCER THERAPY USING TOLL-LIKE RECEPTOR AGONISTS

Country Status (7)

Country Link
EP (1) EP4313315A4 (https=)
JP (1) JP2024512765A (https=)
KR (1) KR20240004419A (https=)
AU (1) AU2022249092A1 (https=)
CA (1) CA3215582A1 (https=)
DE (1) DE112022001882T9 (https=)
WO (1) WO2022212690A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024243794A1 (en) * 2023-04-06 2025-11-06 Trisalus Life Sciences, Inc. System and device for providing localized turbulence for delivering a medical embolizing agent

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170326232A1 (en) * 2016-04-15 2017-11-16 Dynavax Technologies Corporation Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer
US20180000851A1 (en) * 2014-12-31 2018-01-04 Checkmate Pharmaceuticals, Inc. Combination tumor immunotherapy
US20180169229A1 (en) * 2015-05-29 2018-06-21 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer
US20210030783A1 (en) * 2018-02-13 2021-02-04 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
EP4217064A1 (en) * 2020-09-22 2023-08-02 TriSalus Life Sciences, Inc. Cancer therapy using toll-like receptor agonists
US20230323368A1 (en) * 2020-01-10 2023-10-12 Sbi Biotech Co., Ltd. Novel tlr9 agonists

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100881923B1 (ko) 2000-12-27 2009-02-04 다이나박스 테크놀로지 코퍼레이션 면역자극 폴리뉴클레오티드 및 그것의 사용 방법
US20040009151A1 (en) * 2002-04-04 2004-01-15 Kay Mark A. Methods for delivering recombinant adeno-associated virus virions to the liver of a mammal
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US7963956B2 (en) * 2003-04-22 2011-06-21 Antisense Pharma Gmbh Portable equipment for administration of fluids into tissues and tumors by convection enhanced delivery technique
US8696698B2 (en) 2009-12-02 2014-04-15 Surefire Medical, Inc. Microvalve protection device and method of use for protection against embolization agent reflux
US8500775B2 (en) 2009-12-02 2013-08-06 Surefire Medical, Inc. Protection device and method against embolization agent reflux
US9539081B2 (en) 2009-12-02 2017-01-10 Surefire Medical, Inc. Method of operating a microvalve protection device
US9770319B2 (en) 2010-12-01 2017-09-26 Surefire Medical, Inc. Closed tip dynamic microvalve protection device
US9968740B2 (en) 2014-03-25 2018-05-15 Surefire Medical, Inc. Closed tip dynamic microvalve protection device
US20160287839A1 (en) 2015-03-31 2016-10-06 Surefire Medical, Inc. Apparatus and Method for Infusing an Immunotherapy Agent to a Solid Tumor for Treatment
US10806893B2 (en) 2017-01-10 2020-10-20 Surefire Medical, Inc. Guiding catheter having shape-retentive distal end
US10588636B2 (en) 2017-03-20 2020-03-17 Surefire Medical, Inc. Dynamic reconfigurable microvalve protection device
US20190298983A1 (en) 2018-01-15 2019-10-03 Surefire Medical, Inc. Injection Port for Therapeutic Delivery
US11850398B2 (en) 2018-08-01 2023-12-26 Trisalus Life Sciences, Inc. Systems and methods for pressure-facilitated therapeutic agent delivery
US12433597B2 (en) 2019-06-04 2025-10-07 Trisalus Life Sciences, Inc. Atraumatic occlusive system with compartment for measurement of vascular pressure change
WO2021011496A1 (en) * 2019-07-12 2021-01-21 Oregon Health & Science University Immunotherapeutic constructs and methods of their use

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180000851A1 (en) * 2014-12-31 2018-01-04 Checkmate Pharmaceuticals, Inc. Combination tumor immunotherapy
US20180169229A1 (en) * 2015-05-29 2018-06-21 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer
US20170326232A1 (en) * 2016-04-15 2017-11-16 Dynavax Technologies Corporation Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer
US20210030783A1 (en) * 2018-02-13 2021-02-04 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
US20230323368A1 (en) * 2020-01-10 2023-10-12 Sbi Biotech Co., Ltd. Novel tlr9 agonists
EP4217064A1 (en) * 2020-09-22 2023-08-02 TriSalus Life Sciences, Inc. Cancer therapy using toll-like receptor agonists

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology(PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma", CLINICALTRIALS.GOV; NCT04935229, 22 June 2021 (2021-06-22), XP093087816, Retrieved from the Internet <URL:https://classic.clinicaltrials.gov/ct2/show/NCT04935229> [retrieved on 20231002] *
FATMA EL ZAHRAA MOHAMED ET AL: "Effect of Toll-Like Receptor 7 and 9 Targeted Therapy to Prevent the Development of Hepatocellular Carcinoma", LIVER INTERNATIONAL, 1 July 2014 (2014-07-01), pages n/a - n/a, XP055129871, ISSN: 1478-3223, DOI: 10.1111/liv.12626 *
MOHAMED FATMA EL ZAHRAA ET AL: "Inhibition of TLR7 and TLR9 Reduces Human Cholangiocarcinoma Cell Proliferation and Tumor Development", DIGESTIVE DISEASES AND SCIENCES, SPRINGER NEW YORK LLC, US, vol. 67, no. 5, 3 May 2021 (2021-05-03), pages 1806 - 1821, XP037856401, ISSN: 0163-2116, [retrieved on 20210503], DOI: 10.1007/S10620-021-06973-9 *
See also references of WO2022212690A1 *
TANAKA JUNICHIRO ET AL: "Functional cell surface expression of toll-like receptor 9 promotes cell proliferation and survival in human hepatocellular carcinomas", INTERNATIONAL JOURNAL OF ONCOLOGY, SPANDIDOS: ATHENS, GR, vol. 37, no. 4, 1 October 2010 (2010-10-01), pages 805 - 814, XP009155225, ISSN: 1791-2423, DOI: 10.3892/IJO_00000730 *

Also Published As

Publication number Publication date
KR20240004419A (ko) 2024-01-11
AU2022249092A9 (en) 2023-10-26
DE112022001882T5 (de) 2024-01-18
CA3215582A1 (en) 2022-10-06
AU2022249092A1 (en) 2023-10-12
JP2024512765A (ja) 2024-03-19
WO2022212690A1 (en) 2022-10-06
DE112022001882T9 (de) 2024-02-29
EP4313315A1 (en) 2024-02-07

Similar Documents

Publication Publication Date Title
EP3836909A4 (en) BIOMARKERS FOR CANCER THERAPY
EP4274898A4 (en) CHIMERIC RECEPTOR THERAPY
CA3254271A1 (en) Polytherapies for Breast Cancer
EP4217064A4 (en) CANCER THERAPY WITH TOLL-LIKE RECEPTOR AGONISTS
EP4313315A4 (en) CANCER THERAPY USING TOLL-LIKE RECEPTOR AGONISTS
EP4216930A4 (en) CANCER THERAPY WITH TOLL-LIKE RECEPTOR AGONISTS
GB202301902D0 (en) Combination therapy for cancer
EP3981473A4 (en) Therapeutic agent for cancer
HK40117032A (en) Combination therapy for cancer
HK40089616A (en) Biomarkers for cancer therapy using mdm2 antagonists
HK40096988A (en) Combination therapy for cancer
HK40101495A (en) Combination therapy with for46 for cancer
HK40097023A (en) Cancer therapy
HK40083565A (en) Cancer therapy
HK40075685A (en) Biomarkers for cancer therapy using mdm2 antagonists
CA3243227A1 (en) POLYTHERAPY AGAINST CANCER
EP4186520A4 (en) CANCER THERAPEUTICS
CA3270936A1 (en) Nanobodies for cancer therapy
HK40115085A (en) Cancer therapy targeting nkg2a
HK40025336B (en) Cancer therapies
CA3267113A1 (en) THERANOSTIC DEVICE FOR CANCER IMMUNOTHERAPY
AU2021903975A0 (en) Therapeutic conjugates
HK40121815A (en) Combination therapies for breast cancer
HK40091716A (en) Therapeutic conjugates
AU2023901714A0 (en) Combination cancer therapy

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20231002

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61P0035000000

Ipc: A61K0031708800

A4 Supplementary search report drawn up and despatched

Effective date: 20250121

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 1/16 20060101ALI20250115BHEP

Ipc: A61P 35/00 20060101ALI20250115BHEP

Ipc: A61K 31/7088 20060101AFI20250115BHEP